5-formyl-1H-pyrrole-3-carboxylic acid | 946847-30-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 5-formyl-1H-pyrrole-3-carboxylic acid
• CAS: 946847-30-9
• 化学式: C₆H₅NO₃
• mdl: MFCD18810347
• 分子量: 139.111
• InChiKey: PEYREWQPLYKTBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-formyl-1H-pyrrole-3-carboxylic acid 在 哌啶 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 为溶剂， 生成 5-{[(3Z)-5-(carbamoylamino)-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-N-[2-(1H-imidazol-5-yl)ethyl]-1H-pyrrole-3-carboxamide
  参考文献：
  名称：

  Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: Optimization of BX-517

  摘要：

  Based on the lead compound BX-517, a series of C-4 ' substituted indolinones have been synthesized and evaluated for PDK1 inhibition. Modification at C-4 ' of the pyrrole afforded potent compounds (7b and 7d) with improved solubility and ADME properties. In this letter, we describe the synthesis, selectivity profile, and pharmacokinetic data of selected compounds. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.060

文献信息

• MCL-1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190352271A1

  公开（公告）日：2019-11-21

  The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.

  本公开涉及通常用于治疗癌症的化合物和药物组合物。
• [EN] BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES<br/>[FR] COMPOSÉS BIOACTIFS POUR LE TRAITEMENT DU CANCER ET DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：PONIARD PHARMACEUTICALS INC

  公开号：WO2009139834A1

  公开（公告）日：2009-11-19

  The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.

  这项发明提供了用于治疗各种恶性疾病，如癌症和包括阿尔茨海默病在内的神经退行性疾病的生物活性化合物。本文所披露的化合物在与这些疾病相关的生物测定中显示出生物活性。提供了药物组合物、组合物和合成方法，以及使用该化合物、组合物和组合物治疗这些疾病的方法。
• 3-(4-amidopyrrol-2-ylmethylidene)-2-indolinone derivatives as portein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20030092917A1

  公开（公告）日：2003-05-15

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯替代的2-吲哚酮化合物及其药用可接受的盐，这些化合物可以调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面具有用处。
• 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
  申请人：SUGEN, INC.

  公开号：US20040102510A1

  公开（公告）日：2004-05-27

  The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，其调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• 3-(4-AMIDOPYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：Guan Huiping

  公开号：US20080045709A1

  公开（公告）日：2008-02-21

  The present invention provides a method to make a pyrrole substituted 2-indolinone compound of the formula

  本发明提供了一种制备式中的吡咯取代的2-吲哚酮化合物的方法。